Menopausal Hormone Therapy Utilization in US Women Based on Insurance Coverage

Overview

This study investigates the association between insurance type and the utilization of menopausal hormone therapy (MHT) among women aged 45 to 64.

Background

Menopause is a significant physiological transition that can lead to various symptoms, notably vasomotor symptoms (VMS), which affect a substantial proportion of women. MHT is the first-line treatment for these symptoms, yet its utilization has declined since the early 2000s due to safety concerns. Understanding the factors influencing MHT usage, including insurance coverage, is crucial.

Data Highlights

No numerical data available in the source material.

Key Findings

• Menopausal hormone therapy (MHT) is the first-line treatment for bothersome vasomotor symptoms (VMS).
• Rates of MHT initiation decreased dramatically after the Women’s Health Initiative trial results in 2002 and 2004.
• Black or African American individuals report more severe VMS but receive less MHT treatment compared to White counterparts.
• Insurance coverage significantly influences access to MHT.
• The study utilized data from the National Health and Nutrition Examination Survey (NHANES) to assess MHT usage among women aged 45 to 64.

Clinical Implications

Healthcare providers should be aware of the disparities in MHT utilization based on insurance type and race. Addressing these disparities may improve access to effective treatment for menopausal symptoms among underserved populations.

Conclusion

The study underscores the importance of insurance coverage in the utilization of MHT and highlights the need for further investigation into treatment disparities among different racial and ethnic groups.

Related Resources & Content

1. Conexiant, Rethinking Menopause Hormone Therapy, 2025 -- Rethinking Menopause Hormone Therapy
2. The ASCO Post, Is Menopausal Hormone Therapy Associated With Increased Breast Cancer Risk?, 2025 -- Is Menopausal Hormone Therapy Associated With Increased Breast Cancer Risk?
3. The ASCO Post, Menopausal Hormone Therapy Use and Risk of Breast Cancer, 2019 -- Menopausal Hormone Therapy Use and Risk of Breast Cancer
4. US Preventive Services Task Force, Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement, 2022 -- Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons
5. The ASCO Post — Differing Patterns of Breast Cancer Risk After Hormone Therapy With Estrogen Plus Progestin or Estrogen Alone
6. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement
7. Vaginal Estrogen Utilization Among Medicare Beneficiaries With Genitourinary Syndrome of Menopause | Obstetrics and Gynecology | JAMA Network Open | JAMA Network